abbvie-developed visual basic application (AbbVie Inc)
90
Structured Review
AbbVie Inc
abbvie-developed visual basic application
Abbvie Developed Visual Basic Application, supplied by AbbVie Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/visual+basic+application/abbvie+developed+visual+basic+application/pm28949521-262-11-11
Average 90 stars, based on 1 article reviews
Abbvie Developed Visual Basic Application, supplied by AbbVie Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/visual+basic+application/abbvie+developed+visual+basic+application/pm28949521-262-11-11
Average 90 stars, based on 1 article reviews
abbvie-developed visual basic application - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Software:Article Title: Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor. Article Snippet: The development of bromodomain and extraterminal domain (BET) bromodomain inhibitors and their examination in clinical studies, particularly in oncology settings, has garnered substantial recent interest.. An effort to generate novel BET bromodomain inhibitors with excellent potency and DMPK properties was initiated based upon elaboration of a simple pyridone core.. Efforts to develop a bidentate interaction with a critical asparagine residue resulted in the incorporation of a pyrrolopyridone core, which improved potency by 9to 19-fold. Control:Article Title: Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor. Article Snippet: The development of bromodomain and extraterminal domain (BET) bromodomain inhibitors and their examination in clinical studies, particularly in oncology settings, has garnered substantial recent interest.. An effort to generate novel BET bromodomain inhibitors with excellent potency and DMPK properties was initiated based upon elaboration of a simple pyridone core.. Efforts to develop a bidentate interaction with a critical asparagine residue resulted in the incorporation of a pyrrolopyridone core, which improved potency by 9to 19-fold. Injection:Article Title: Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor. Article Snippet: The development of bromodomain and extraterminal domain (BET) bromodomain inhibitors and their examination in clinical studies, particularly in oncology settings, has garnered substantial recent interest.. An effort to generate novel BET bromodomain inhibitors with excellent potency and DMPK properties was initiated based upon elaboration of a simple pyridone core.. Efforts to develop a bidentate interaction with a critical asparagine residue resulted in the incorporation of a pyrrolopyridone core, which improved potency by 9to 19-fold. |